NGENLA 60 mg, solution for injection in a pre-filled pen pen, 1.2 ml
Active ingredients: SOMATROGON
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionpen, 1.2 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NGENLA 60 mg, solution injectable en stylo prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 cartouche(s) en verre de 1,2 ml dans stylo pré-rempli
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 9 May 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
61429758CIP73024727CIP133400930247273Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SOMATROGONsolution | 60 mg · un stylo prérempli de 1,2 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.